Share：
Share this content in WeChat
X
[Chinese][PDF]7935
• Clinical Article •
A comparative study on the clinical application of domestic hepatobiliary specific contrast agent and foreign hepatobiliary specific contrast agent Gd-EOB-DTPA
WEI Huanhuan  FU Fangfang  YANG Yan  Bai Yan  WEI Wei  YU Xuan  GAO Haiyan  CHEN Lijuan  WANG Meiyun 

Cite this article as: WEI H H, FU F F, YANG Y, et al. A comparative study on the clinical application of domestic hepatobiliary specific contrast agent and foreign hepatobiliary specific contrast agent Gd-EOB-DTPA[J]. Chin J Magn Reson Imaging, 2023, 14(1): 89-93. DOI:10.12015/issn.1674-8034.2023.01.016.


[Abstract] Objective To investigate the comparative analysis of different hepatobiliary specific contrast agents and their value in liver function grading evaluation.Materials and Methods The imaging data of patients with pathologically confirmed or clinically diagnosed chronic liver disease in Henan Provincial People's Hospital from June 2018 to July 2020 were retrospectively analyzed. A total of 162 patients were included and divided into two groups according to different contrast medium, including 81 patients who underwent domestic contrast enhancement and 81 patients who underwent originator contrast enhancement. The quality of MRI images in arterial phase, portal venous phase, equilibrium phase and hepatobiliary phase was assessed in both groups. The contrast enhancement index (CEI) was calculated by measuring the relative ratio of the unenhanced masked image (SIpre) to the relative ratio of the hepatobiliary specific phase after enhancement (SIpost), CEI=SIpost/SIpre. The clinical data of all patients were collated and analyzed for Child-Pugh classification of liver function, the difference in CEI between domestic contrast medium and original contrast medium was assessed and the correlation between CEI of the two contrasts medium and Child-Pugh classification of liver function was explored, respectively.Results There was no significant difference in MRI images quality assessment between the two contrasts medium, and the consistency between the two assessors was high. The mean CEI of domestic gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA) contrast medium in Child-Pugh classification A and B of liver function was 1.28-1.87 (1.40±0.14) and 1.00-1.28 (1.15±0.07), and there was a significant difference in the CEI between Child-Pugh A group and Child-Pugh B group (P＜0.001). The mean CEI of originator contrasts medium Gd-EOB-DTPA was 1.30-1.67 (1.40±0.09) and 1.00-1.29 (1.18±0.08), and there was a significant difference in the CEI between Child-Pugh A group and Child-Pugh B group (P＜0.001). There was no significant difference in the CEI between the two groups under the same Child-Pugh classification of liver function (all P＞0.05); with the decrease of liver function, the CEI of both groups decreased.Conclusions Domestic Gd-EOB-DTPA contrast medium and foreign Gd-EOB-DTPA contrast medium showed high similarity in enhanced images of liver diseases, and there was no significant difference in diagnostic efficacy. The subjective item evaluation and quantitative parameter evaluation of Gd-EOB-DTPA contrast enhanced MRI images have good analysis results, which can provide important clinical value for the evaluation of liver function in patients with chronic liver disease.
[Keywords] liver；liver function；hepatobiliary specific contrast agent；Gd-EOB-DTPA；comparison and analysis；contrast enhancement index；magnetic resonance imaging

WEI Huanhuan1   FU Fangfang2   YANG Yan1   Bai Yan2   WEI Wei2   YU Xuan2   GAO Haiyan2   CHEN Lijuan2   WANG Meiyun2*  

1 Department of Imaging, People's Hospital of Zhengzhou University, Zhengzhou 450003, China

2 Department of Imaging, Henan Provincial People's Hospital, Zhengzhou 450003, China

Corresponding author: Wang MY, E-mail: mywang@ha.edu.cn

Conflicts of interest   None.

ACKNOWLEDGMENTS Henan Provincial Science and Technology Research Project (No. 212102310689).
Received  2022-07-13
Accepted  2022-12-05
DOI: 10.12015/issn.1674-8034.2023.01.016
Cite this article as: WEI H H, FU F F, YANG Y, et al. A comparative study on the clinical application of domestic hepatobiliary specific contrast agent and foreign hepatobiliary specific contrast agent Gd-EOB-DTPA[J]. Chin J Magn Reson Imaging, 2023, 14(1): 89-93. DOI:10.12015/issn.1674-8034.2023.01.016.

[1]
WEN X, FENG X, KANG Y, et al. Application progress of Gd-EOB-DTPA-enhanced MRI T1 mapping in hepatic diffuse diseases[J]. Curr Med Imaging, 2022, 18(12): 1276-1281. DOI: 10.2174/1573405617666211130153450.
[2]
SUZUKI T, AONUMA T, OYAMA K, et al. High-resolution three-dimensional T1-weighted hepatobiliary MR cholangiography using Gd-EOB-DTPA for assessment of biliary tree anatomy: parallel imaging versus compressed sensing[J/OL]. Eur J Radiol, 2021, 136: 109515 [2022-11-26]. https://www.ejradiology.com/article/S0720-048X(20)30705-1/fulltext. DOI: 10.1016/j.ejrad.2020.109515.
[3]
DING C, BAI G J. Advances in the evaluation of liver reserve function by Gd-EOB-DTPA-MRI[J]. Chin J Magn Reson Imaging, 2021, 12(8): 104-107. DOI: 10.12015/issn.1674-8034.2021.08.024.
[4]
WANG Y J, ZHANG L, NING J, et al. Preoperative remnant liver function evaluation using a routine clinical dynamic Gd-EOB-DTPA-enhanced MRI protocol in patients with hepatocellular carcinoma[J]. Ann Surg Oncol, 2021, 28(7): 3672-3682. DOI: 10.1245/s10434-020-09361-1.
[5]
HU J H, WANG X X, CHEN J F, et al. The differential diagnosis value of quantitative parameters of hepatobiliary phase from Gd-EOB-DTPA enhanced MRI in differentiating benign biliary strictures from malignant strictures[J]. Chin J Magn Reson Imaging, 2022, 13(6): 117-121. DOI: 10.12015/issn.1674-8034.2022.06.023.
[6]
DING C, JIA J Y, BAI G J, et al. Predictive value of Gd-EOB-DTPA-enhanced magnetic resonance imaging for post-hepatectomy liver failure: a systematic review and meta-analysis[J/OL]. Acta Radiol, 2022: 2841851221134485 [2022-11-26]. https://journals.sagepub.com/doi/10.1177/02841851221134485?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed. DOI: 10.1177/02841851221134485.
[7]
WU Y, ZHU M L, LIU Y M, et al. Peritumoral imaging manifestations on Gd-EOB-DTPA-enhanced MRI for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and Meta-analysis[J/OL]. Front Oncol, 2022, 12: 907076 [2022-11-26]. https://www.frontiersin.org/articles/10.3389/fonc.2022.907076/full. DOI: 10.3389/fonc.2022.907076.
[8]
HUANG X L, PENG J. Progress of Gd-EOB-DTPA in the diagnosis and evaluation of CRLM[J]. Chin J Magn Reson Imaging, 2021,12(10):112-114,124. DOI: 10.12015/issn.1674-8034.2021.10.029.
[9]
International Exchange Group of Chinese Society of Imaging Technology. Expert consensus on hepatobiliary specific contrast agent gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid enhanced MRI scanning scheme[J]. Chin J Radiol, 2019(12): 1040-1044. DOI: 10.3760/cma.j.issn.1005-1201.2019.12.005.
[10]
WATANABE H, KANEMATSU M, GOSHIMA S, et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging: preliminary observations[J]. Radiology, 2011, 259(1): 142-150. DOI: 10.1148/radiol.10100621.
[11]
IMURA S, SHIMADA M, UTSUNOMIYA T. Recent advances in estimating hepatic functional reserve in patients with chronic liver damage[J]. Hepatol Res, 2015, 45(1): 10-19. DOI: 10.1111/hepr.12325.
[12]
LI X Q, WANG X, ZHAO D W, et al. Application of Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma[J/OL]. World J Surg Oncol, 2020, 18(1): 219 [2022-11-26]. https://wjso.biomedcentral.com/articles/10.1186/s12957-020-01996-4. DOI: 10.1186/s12957-020-01996-4.
[13]
MURAKAMI T, SOFUE K, HORI M. Diagnosis of hepatocellular carcinoma using Gd-EOB-DTPA MR imaging[J]. Magn Reson Med Sci, 2022, 21(1): 168-181. DOI: 10.2463/mrms.rev.2021-0031.
[14]
WANG W T. T1 mapping on gadoxetic acid-enhanced MR imaging predicts recurrence of hepatocellular carcinoma after hepatectomy[J]. Eur J Radiol, 2018, 103: 25-31. DOI: 10.1016/j.ejrad.2018.03.027.
[15]
KUDO M. Early hepatocellular carcinoma: definition and diagnosis[J]. Liver Cancer, 2013, 2(2): 69-72. DOI: 10.1159/000343842.
[16]
MULÉ S, CHALAYE J, LEGOU F, et al. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT[J]. Eur Radiol, 2020, 30(10): 5348-5357. DOI: 10.1007/s00330-020-06923-5.
[17]
ZHAO Q Y, QI Y G, GUO S F, et al. The value of Gd-EOB-DTPA enhanced magnetic resonance imaging for predicting early recurrence of hepatocellular carcinoma after resection[J]. Chin J Magn Reson Imaging, 2021, 12(12): 18-23. DOI: 10.12015/issn1674-8034.2021.12.004.
[18]
KANG H J, KIM H, LEE D H, et al. Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery[J]. Radiology, 2021, 300(3): 572-582. DOI: 10.1148/radiol.2021204352.
[19]
POETTER-LANG S, BASTATI N, MESSNER A, et al. Quantification of liver function using gadoxetic acid-enhanced MRI[J]. Abdom Radiol (NY), 2020, 45(11): 3532-3544. DOI: 10.1007/s00261-020-02779-x.
[20]
IPPOLITO D, PECORELLI A, FAMULARO S, et al. Assessing liver function: diagnostic efficacy of parenchymal enhancement and liver volume ratio of Gd-EOB-DTPA-enhanced MRI study during interstitial and hepatobiliary phase[J]. Abdom Radiol (NY), 2019, 44(4): 1340-1349. DOI: 10.1007/s00261-018-1812-9.
[21]
YANG M, ZHANG Y, ZHAO W L, et al. Evaluation of liver function using liver parenchyma, spleen and portal vein signal intensities during the hepatobiliary phase in Gd-EOB-D TPA-enhanced MRI[J/OL]. BMC Med Imaging, 2020, 20(1): 119 [2022-11-26]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576754/. DOI: 10.1186/s12880-020-00519-7.
[22]
LI A Q, WU J, CHENG J, et al. Gd-EOB-DTPA-enhanced MRI-a noninvasive and short-term assessment method for liver necroinflammation after direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C[J]. Abdom Radiol (NY), 2022, 47(1): 174-183. DOI: 10.1007/s00261-021-03316-0.
[23]
LIU M T, LU J, ZHANG X Q, et al. Evaluation of liver function with hepatocyte fraction based on Gd-EOB-DTPA-enhanced liver MRI[J]. Chin J Med Imaging Technol, 2020, 36(10): 1490-1494. DOI: 10.13929/j.issn.1003-3289.2020.10.012.
[24]
PLAIKNER M, KREMSER C, ZOLLER H, et al. Does gadoxetate disodium affect MRE measurements in the delayed hepatobiliary phase?[J]. Eur Radiol, 2019, 29(2): 829-837. DOI: 10.1007/s00330-018-5616-7.

PREV Radiomics for the preoperative prediction of microvascular invasion in hepatocellular carcinoma: A systemic review and Meta-analysis
NEXT Preoperative prediction of vascular invasion in rectal cancer patients without lymph node metastasis based on multimodal MRI imaging features combined with clinical risk factors
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn